share_log

仟源医药(300254.SZ):已取得治疗癫痫症的二类精神药品CYRJ2308的实验研究立项批件

Qianyuan Pharmaceutical (300254.SZ): An experimental research project approval for CYRJ2308, a class II psychotropic drug for treating epilepsy has been obtained

Gelonghui Finance ·  Mar 29 03:21

Gelonghui March 29丨Qianyuan Pharmaceutical (300254.SZ) was surveyed by specific subjects on March 28, 2024, on “What are the areas of refined narcotics developed by the company?” The company replied that the company has obtained approval for experimental research on CYRJ2308, a class II psychotropic drug to treat epilepsy, and that the company will also apply for research and development of project varieties in the fields of depression and migraine treatment.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment